Multithread effectively and personalize outreach to convert deals faster
Elevate social presence and drive business growth from social media
Identify and prioritize high-intent leads, and improve sales effectiveness
Find and connect with ICP attendees, and improve event outcomes
Magenta Therapeutics (formerly NASDAQ: MGTA) was a clinical-stage biotechnology company that focused on developing novel medicines to bring the curative power of stem cell transplant to more patients with autoimmune diseases, blood cancers, and genetic diseases. The company's programs aimed to improve patient conditioning, stem cell mobilization, and cell engraftment. In early 2023, Magenta Therapeutics announced the discontinuation of its programs, including its lead candidate MGTA-117, following a patient death in a clinical trial. Subsequently, the company underwent a significant restructuring, workforce reduction, and ultimately pursued a plan of complete dissolution and liquidation.
The Cambridge headquarters served as the central hub for Magenta Therapeutics' research and development, clinical operations, and corporate functions before the company ceased operations.
Located within Technology Square, a well-known campus for tech and life science companies, offering modern laboratory and office facilities.
Prior to its dissolution, the work culture at Magenta Therapeutics was likely characterized by a strong focus on scientific innovation, collaboration, and a fast-paced environment typical of clinical-stage biotech companies aiming to address significant unmet medical needs. (Note: Company has ceased operations).
The Cambridge location provided strategic advantages, including proximity to world-class research institutions, a rich talent pool in biotechnology, and a vibrant ecosystem of collaborators and service providers.
As a clinical-stage biotechnology company, Magenta Therapeutics' global presence was primarily through its clinical trial sites, which were conducted in collaboration with hospitals and research institutions in various countries. The company did not maintain a significant network of international offices for general business operations. All operations have ceased.
100 Technology Square, 5th Floor
Cambridge
MA
USA
No additional office locations available.
Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.
As of April 2025, Magenta Therapeutics' leadership includes:
Magenta Therapeutics has been backed by several prominent investors over the years, including:
The 12-18 months leading up to Magenta Therapeutics' dissolution in 2023 were marked by significant challenges, including clinical trial setbacks, which ultimately led to the departure of its executive team as part of the company's wind-down.
Discover the tools Magenta Therapeutics uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.
Based on common patterns for companies of its size and industry, Magenta Therapeutics likely used standard email formats. These email addresses are no longer active due to the company's cessation of operations.
jdoe@magentatx.com (first_initial)(last) or jane.doe@magentatx.com (first).(last)
Format
example@magentatx.com
Example
0%
Success rate
GlobeNewswire • April 27, 2023
Magenta Therapeutics announced that its Board of Directors approved a plan of complete dissolution and liquidation of the Company. This decision followed a comprehensive review of strategic alternatives after the company discontinued its clinical programs....more
Fierce Biotech • February 10, 2023
Magenta Therapeutics announced it was halting all further development of its programs, including its lead antibody-drug conjugate MGTA-117, following a patient death in a Phase I/II trial. The company also stated it would explore strategic alternatives and implement a significant workforce reduction....more
BioSpace • January 26, 2023
Magenta Therapeutics reported that a patient dosed with MGTA-117 in its Phase I/II study in relapsed/refractory acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) had died. As a result, the company voluntarily paused dosing in the trial to review the event....more
See where a company’s workforce is located, by country or region.
View past and recent funding rounds with amounts and investors.
Understand company revenue estimates and financial scale.
Track active roles and hiring trends to spot growth signals.
Discover what a company offers—products, platforms, and solutions.
Get the company’s official SIC and NAICS classifications.
Analyze visitor volume, engagement, and top traffic sources.
Explore LinkedIn, Twitter, and other active social profiles.
Identify top competitors based on similar business traits.
Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.
Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.
Thousands of companies, including Magenta Therapeutics, are just a search away.